Sirukumab: A novel therapy for lupus nephritis?

Uma Thanarajasingam, Timothy B. Niewold

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

Original languageEnglish (US)
Pages (from-to)1449-1455
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Lupus Nephritis
Systemic Lupus Erythematosus
Therapeutics
Morbidity
Recurrence
Mortality
sirukumab

Keywords

  • Biologic
  • Human
  • IL-6
  • Lupus nephritis
  • Monoclonal antibody
  • Sirukumab
  • Systemic lupus erythematosus
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sirukumab : A novel therapy for lupus nephritis? / Thanarajasingam, Uma; Niewold, Timothy B.

In: Expert Opinion on Investigational Drugs, Vol. 23, No. 10, 01.10.2014, p. 1449-1455.

Research output: Contribution to journalArticle

@article{0bbc575461c747dda27bdd0c8c07dda5,
title = "Sirukumab: A novel therapy for lupus nephritis?",
abstract = "Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.",
keywords = "Biologic, Human, IL-6, Lupus nephritis, Monoclonal antibody, Sirukumab, Systemic lupus erythematosus, Therapy",
author = "Uma Thanarajasingam and Niewold, {Timothy B.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1517/13543784.2014.950837",
language = "English (US)",
volume = "23",
pages = "1449--1455",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Sirukumab

T2 - A novel therapy for lupus nephritis?

AU - Thanarajasingam, Uma

AU - Niewold, Timothy B.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

AB - Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

KW - Biologic

KW - Human

KW - IL-6

KW - Lupus nephritis

KW - Monoclonal antibody

KW - Sirukumab

KW - Systemic lupus erythematosus

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84907045551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907045551&partnerID=8YFLogxK

U2 - 10.1517/13543784.2014.950837

DO - 10.1517/13543784.2014.950837

M3 - Article

C2 - 25189410

AN - SCOPUS:84907045551

VL - 23

SP - 1449

EP - 1455

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 10

ER -